Proteon Therapeutics initiated at Maxim

Proteon Therapeutics initiated with a Buy at Maxim. Maxim analyst Jason McCarthy initiated Proteon Therapeutics with a Buy rating and a price target of $5. The analyst notes the evaluation of the company’s Vonapanitase in its second expanded phase 3 trial in hemodialysis fistula creation with data expected in March of 2019. McCarthy states that the protocol amendments of this PATENCY-2 study support his view of a positive outcome, adding that the stock trades at an attractive valuation on risk-reward basis.
https://thefly.com/landingPageNews.php?id=2813321